Everything below concerns SR9009. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-25. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
The Black Mesa Research Facility (also simply called Black Mesa) is a fictional large underground laboratory complex that serves as the primary setting for the video game Half-Life and its expansions, as well as its unofficial remake, Black Mesa. It also features in the wider Half-Life universe, including the Portal series. Located in the New Mexico desert in a decommissioned Cold War missile site, it is the former employer of Half-Life's theoretical physicist protagonist, Gordon Freeman, and a competitor of Aperture Science. While the facility ostensibly conducts military-industrial research, its secret experiments into teleportation have caused it to make contact with the alien world of Xen, and its scientists covertly study its life-forms and materials. In a catastrophic event known as the "Black Mesa Incident", an "anti-mass spectrometer" experiment conducted on Xen matter causes a Resonance Cascade disaster that allows aliens to invade Earth, and is the catalyst for the events of the series. Half-Life was critically acclaimed for its storytelling and level design. At the time, the integration of narrative into gameplay through scripted sequences and NPCs instead of through cutscenes was considered groundbreaking for a first-person shooter.
=== Interventions Testing Program === The Interventions Testing Program (ITP) is one of three National Institute on Aging (NIA)-supported testing sites that comprise the nationally coordinated Interventions Testing Program. The ITP was established by the NIA to rigorously evaluate pharmacological, nutritional, and biological interventions with the potential to extend lifespan, improve healthspan, and delay the onset of age-related diseases. Through a highly standardized, multi-institutional testing framework, the Program identifies interventions that target the fundamental biology of aging rather than individual diseases, providing critical preclinical evidence to guide future translational and clinical research. The Barshop Institute serves as a major testing center within the national ITP consortium, collaborating closely with partner institutions to conduct large-scale lifespan and healthspan studies using genetically heterogeneous mouse models. Unlike studies utilizing inbred strains, the genetically diverse mice employed by the ITP more closely reflect the genetic variability observed in human populations, increasing the translational relevance of study findings. Candidate interventions are proposed by investigators from across the scientific community and undergo a rigorous scientific review process before being selected for testing.
The first and most important step in sample preparation for mass spectrometry is determining what phase the sample needs to be in. Different ionization methods require different sample phases. Solid phase samples can be ionized through methods such as field desorption, plasma-desorption, fast atom bombardment, and secondary-ion ionization. Liquids with the analyte dissolved in them, or solutions, can be ionized through methods such as matrix-assisted laser desorption, electrospray ionization, and atmospheric-pressure chemical ionization. Both solid and liquid samples may be ionized with ambient ionization techniques. Gas samples, or volatile samples, can be ionized using methods such as electron ionization, photoionization, and chemical ionization. These lists are the most commonly used state of matter for each ionization method, but the ionization methods are not necessarily limited to these states of matter. For example, fast atom bombardment ionization is typically used to ionize solid samples, but this method is typically used on solids dissolved into solutions, and can also be used to analyze components that have entered the gas phase.
Sources: en.wikipedia.org
== Investment == The basic elements of an investment are cash inflows, outflows, timing of cash flows, and risk. The ability to analyze these elements is key in providing services to investors in commercial real estate.
In 1996, Saccharomyces cerevisiae was the first single-celled, eukaryotic organism to have its entire genome sequenced. This sequencing helped confirm the nearly century of work by mycologists and enologists in identifying different strains of Saccharomyces cerevisiae that are used in beer, bread and winemaking. Today there are several hundred different strains of S. cerevisiae identified. Not all of the strains are suitable for winemaking and even among the strains that are, there is debate among winemakers and scientists about the actual magnitude of differences between the various strains and their potential impact on the wine. Even among strains that have demonstrated distinctive difference when compared among young wines, these differences seem to fade and become less distinctive as the wines age. Some distinct difference among various strains include the production of certain "off-flavor" and aromas that may be temporary (but producing a "stinky fermentation") or could stay with the wine and either have to be dealt with through other winemaking means (such as the presence of volatile sulfur compounds like hydrogen sulfide) or leave a faulty wine. Another difference includes the "vigor" or speed of fermentation (which can also be influenced by other factors beyond yeast selection) with some yeast strains having the tendency to do "fast ferments" while others may take longer to get going.
== Ban == The BBB was banned, and restrictions were placed on the political activities of Schabort in November 1988, in reaction to the massacre of black South Africans in Pretoria by Barend Strydom. This was the first time such restrictions had been placed on a right wing organisation. In banning the group, Adriaan Vlok, the Law and Order Minister, said that the group were "right-wing, fanatical extremists who favour violence to carry racism to its extreme". In December 1988, Schabort re-launched the BBB as the Blanke Nasionale Beweging (White National Movement) under the nominal leadership of Wynand de Beer; however, as its activities were clearly the same as the BBB, it was banned at the beginning of 1989. The government lifted the ban on the BBB in February 1990. Schabort officially disbanded the BBB and the Blanke Party in 1990, and joined the Conservative Party. Some members of the BBB, like Keith Conroy, would go on to support the Afrikaner Volksfront.
ribozyme An RNA molecule with enzymatic activity, i.e. one that is capable of catalyzing one or more specific biochemical reactions, similar to protein enzymes. Ribozymes function in numerous capacities, including in ribosomes as part of the large subunit ribosomal RNA.
Sources: en.wikipedia.org
== Education == Tack received his Bachelor of Arts degree in physical chemistry from Princeton University in 1961 and his PhD from the University of California, Berkeley in 1965 for spectroscopic studies of photosynthesis.
The first application of barrier membranes in the mouth occurred in 1982 in the context of regeneration of periodontal tissues via GTR, as an alternative to resective surgical procedures to reduce pocket depths. A barrier membrane is utilized in the GBR technique to cover the bone defect and create a secluded space, which prevents the connective tissue from growing into the space and facilitates the growth priority of bone tissue. An added benefit of the membrane is that it provides protection of the wound from mechanical disruption and salivary contamination. Barrier membrane criteria should be as follows:
==== Notable early bodybuilders ==== Many other important bodybuilders in the early history of bodybuilding prior to 1930 include: Earle Liederman (writer of some of bodybuilding's earliest books), Zishe Breitbart, George Hackenschmidt, Emy Nkemena, George F. Jowett, Finn Hateral (a pioneer in the art of posing), Frank Saldo, Monte Saldo, William Bankier, Launceston Elliot, Sig Klein, Sgt. Alfred Moss, Joe Nordquist, Lionel Strongfort ("Strongfortism"), Gustav Frištenský, Ralph Parcaut (a champion wrestler who also authored an early book on "physical culture"), and Alan P. Mead (who became a muscle champion despite the fact that he lost a leg in World War I). Actor Francis X. Bushman, who was a disciple of Sandow, started his career as a bodybuilder and sculptor's model before beginning his famous silent movie career.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.